MLICM
MRSN

Metropolitan Life Insurance Company (MetLife)’s Mersana Therapeutics MRSN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-187
Closed -$21K – 1316
2024
Q1 		$21K Buy
187
+125
+202% +$12.4K ﹤0.01% 1837
2023
Q4 		$3.62K Sell
62
-142
-70% -$5.71K ﹤0.01% 2302
2023
Q3 		$6.49K Hold
204
– – ﹤0.01% 2369
2023
Q2 		$16.8K Buy
204
+49
+32% +$7.17K ﹤0.01% 2023
2023
Q1 		$16K Sell
155
-105
-40% -$14.7K ﹤0.01% 1990
2022
Q4 		$38.1K Buy
260
+70
+37% +$11.8K ﹤0.01% 1637
2022
Q3 		$32.2K Hold
190
– – ﹤0.01% 1754
2022
Q2 		$22K Hold
190
– – ﹤0.01% 2008
2022
Q1 		$19K Sell
190
-191
-50% -$22.3K ﹤0.01% 2123
2021
Q4 		$59.2K Sell
381
-217
-36% -$42.2K ﹤0.01% 2684
2021
Q3 		$141K Sell
598
-193
-24% -$56.4K ﹤0.01% 2321
2021
Q2 		$269K Buy
791
+207
+35% +$78.4K ﹤0.01% 1945
2021
Q1 		$236K Sell
584
-49
-8% -$23.8K ﹤0.01% 1903
2020
Q4 		$421K Buy
633
+14
+2% +$7.79K 0.01% 1466
2020
Q3 		$288K Buy
619
+45
+8% +$22.7K ﹤0.01% 1564
2020
Q2 		$336K Buy
574
+366
+176% +$125K 0.01% 1476
2020
Q1 		$30.3K Buy
+208
New +$36.3K ﹤0.01% 2421

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MRSN Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 187 shares — an estimated $21K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MRSN in Q1 2020 and held it in 17 quarters. The position peaked at $421K in Q4 2020. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 187 Mersana Therapeutics shares in Q2 2024, an estimated $21K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Mersana Therapeutics in Q1 2020 and held it in 17 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Mersana Therapeutics position peaked at $421K in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.